Performance of standardized patient reported outcomes developed for spondyloarthritis in primary and concomitant forms of fibromyalgia

Table 2 Baseline scores of different items of all patients related to the diagnoses pFM or axSpA or PsA with cFM or without FM

	FM	axSpA-	p-value axSpA- vs. FM	axSpA+	p-value axSpA + vs. FM	PsA-	p-value PsA- vs. FM	PsA+	p-value PsA + vs. FM
BADSAI	6.9 ± 1.4	5.2 ± 2.0	< 0.001	6.9 ± 1.4	0.858	---	---	---	---
ASDAS-CRP	3.3 ± 0.6	3.1 ± 1.0	0.086	3.7 ± 1.2	0.208	---	---	---	---
BASFI	6.4 ± 2.1	5.4 ± 2.5	0.005	7.1 ± 1.8	0.41	---	---	---	---
DAPSA	43.0 ± 17.8	---	---	---	---	32.0 ± 18.6	< 0.001	46.5 ± 19.7	0.37
FIQ	68.5 ± 13.5	53.9 ± 21.2	< 0.001	72.3 ± 13.7	0.352	57.2 ± 18.3	< 0.001	68.5 ± 11.6	0.978
LEI	4.0 ± 1.6	1.5 ± 1.7	< 0.001	3.3 ± 1.4	0.179	2.4 ± 2.0	< 0.001	3.6 ± 2.0	0.625
MASES	8.6 ± 3.0	3.4 ± 3.3	< 0.001	8.2 ± 2.9	0.642	4.2 ± 3.6	< 0.001	7.1 ± 3.6	0.101
SPARCC	9.4 ± 3.4	3.5 ± 3.4	< 0.001	7.7 ± 3.8	0.139	5.1 ± 3.7	< 0.001	8.1 ± 3.9	0.412

Fibromyalgia (FM); axial spondyloarthritis (axSpA); psoriatic arthritis (PsA), BASDAI: Bath Ankylosing Spondylitis Disease Activity Index BASFI: Bath Ankylosing Spondylitis Functioning Index
axSpA-: axSpA without concomitant FM (cFM), axSpA+: axSpA with cFM, PsA-: PsA without cFM, PsA+: PsA with cFM

ISSN: 1478-6362